A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
Looking at stem cells through physicists’ eyes is challenging some of our basic assumptions about the body’s master cells.
Scientists at the University of Cambridge have identified a key chemical that can repair the damage to cells which causes a rare but devastating disease involving accelerated ageing. As well as offering a promising new way of treating the condition, known as Hutchinson-Gilford Progeria Syndrome (HGPS), the discovery could help in the development of drugs against cancer and other genetic diseases and might also suggest ways to alleviate diseases that we associate with normal ageing.
Cambridge research that has for the first time successfully grown “mini-livers” from adult mouse stem cells has won the UK’s international prize for the scientific and technological advance with the most potential to replace, reduce or refine the use of animals in science (the 3Rs).
The Indian Prime Minister, Dr Manmohan Singh, announced at the 101st Annual Session of the Indian Science Congress that Professor Azim Surani of the Gurdon Institute has been awarded the prestigious Jawaharlal Nehru Fellowship by the Government of India’s Department of Science and Technology.
We know much about how embryos develop, but one key stage – implantation – has remained a mystery. Now, scientists from Cambridge have discovered a way to study and film this ‘black box’ of development.
Research reveals the mechanism of epigenetic reprogramming.
The Nobel Prize in Physiology or Medicine has today been jointly awarded to Professor Sir John Gurdon, Emeritus Professor in Cell Biology currently at the University’s Gurdon Institute, along with Professor Shinya Yamanaka of Kyoto University, for their pioneering work in stem cell research.
New drug could treat mixed-lineage leukaemia (MLL).
Patients who have benefited from life saving experimental cancer treatments will join world class researchers for a public open day.
© 2025 University of Cambridge